>
Neuronetics Inc logo

STIM - Neuronetics Inc Share Price

$5.23 0.2  3.8%

Last Trade - 19/10/21

Sector
Healthcare
Size
Small Cap
Market Cap £96.6m
Enterprise Value £37.7m
Revenue £39.7m
Position in Universe 5266th / 7245
Bullish
Bearish
Unlock STIM Revenue
Momentum
Relative Strength (%)
1m -23.7%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -77.5%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 34.2 40.4 52.8 62.7 49.2 55.8 68.7 +9.5%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2021, NeuroneticsInc revenues increased 25% to $26.5M. Net loss decreased24% to $15.4M. Revenues reflect United States segmentincrease of 25% to $25.6M, International segment increaseof 14% to $880K. Lower net loss reflects Sales andmarketing - Balancing value decrease of 9% to $16.5M(expense), Loss on extinguishment of debt decrease from$924K (expense) to $0K.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

STIM Revenue Unlock STIM Revenue

Net Income

STIM Net Income Unlock STIM Revenue

Normalised EPS

STIM Normalised EPS Unlock STIM Revenue

PE Ratio Range

STIM PE Ratio Range Unlock STIM Revenue

Dividend Yield Range

STIM Dividend Yield Range Unlock STIM Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
STIM EPS Forecasts Unlock STIM Revenue
Profile Summary

Neuronetics, Inc. is a commercial-stage medical technology company. The Company is focused on designing, developing, and marketing products to treat psychiatric disorders. Its primary product includes NeuroStar Advanced Therapy System, which is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation (TMS), to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The NeuroStar Advanced Therapy System is used to treat depressive disorder. The Company sells NeuroStar Advanced Therapy System and recurring treatment Sessions in the United States.

Directors
Last Annual December 31st, 2020
Last Interim June 30th, 2021
Incorporated July 3, 2001
Public Since June 28, 2018
No. of Shareholders: 146
No. of Employees: 161
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index Nasdaq Composite ,
Exchange NASDAQ Global Market
Shares in Issue 26,318,346
Free Float (0.0%)
Eligible for
ISAs
SIPPs
STIM Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for STIM
Upcoming Events for STIM
Monday 1st November, 2021 Estimate
Q3 2021 Neuronetics Inc Earnings Release
Monday 28th February, 2022 Estimate
Q4 2021 Neuronetics Inc Earnings Release
Frequently Asked Questions for Neuronetics Inc
What is the Neuronetics Inc share price?

As of 19/10/21, shares in Neuronetics Inc are trading at $5.23, giving the company a market capitalisation of £96.6m. This share price information is delayed by 15 minutes.

How has the Neuronetics Inc share price performed this year?

Shares in Neuronetics Inc are currently trading at $5.23 and the price has moved by -19.36% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Neuronetics Inc price has moved by -38.2% over the past year.

What are the analyst and broker recommendations for Neuronetics Inc?

Of the analysts with advisory recommendations for Neuronetics Inc, there are there are currently 1 "buy" , 2 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Neuronetics Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Neuronetics Inc next release its financial results?

Neuronetics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2022-06-30
What is the Neuronetics Inc dividend yield?

Neuronetics Inc does not currently pay a dividend.

Does Neuronetics Inc pay a dividend?

Neuronetics Inc does not currently pay a dividend.

When does Neuronetics Inc next pay dividends?

Neuronetics Inc does not currently pay a dividend.

How do I buy Neuronetics Inc shares?

To buy shares in Neuronetics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Neuronetics Inc?

Shares in Neuronetics Inc are currently trading at $5.23, giving the company a market capitalisation of £96.6m.

Where are Neuronetics Inc shares listed? Where are Neuronetics Inc shares listed?

Here are the trading details for Neuronetics Inc:

Country of listing: United States
Exchange: NMQ
Ticker Symbol: STIM
What kind of share is Neuronetics Inc?

Based on an overall assessment of its quality, value and momentum, Neuronetics Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Neuronetics Inc share price forecast 2021?

Shares in Neuronetics Inc are currently priced at $5.23. At that level they are trading at 0.158% discount to the analyst consensus target price of 0.00.

Analysts covering Neuronetics Inc currently have a consensus Earnings Per Share (EPS) forecast of -1.19 for the next financial year.

How can I tell whether the Neuronetics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Neuronetics Inc. Over the past six months, the relative strength of its shares against the market has been -59.61%. At the current price of $5.23, shares in Neuronetics Inc are trading at -59.53% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Neuronetics Inc PE Ratio?

We were not able to find PE ratio data for Neuronetics Inc.

Who are the key directors of Neuronetics Inc?

Neuronetics Inc's management team is headed by:

Wilfred Jaeger - IND
Stephen Furlong - CFO
Sheryl Conley - IND
W. Andrew Macan - SVP
Keith Sullivan - PRE
John Bakewell - IND
Cory Anderson - VPR
Robert Cascella - IND
Todd Cushman - VBD
Who are the major shareholders of Neuronetics Inc?

Here are the top five shareholders of Neuronetics Inc based on the size of their shareholding:

First Light Asset Management, LLC Investment Advisor/Hedge Fund
Percentage owned: 5.56% (1.46m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 5.3% (1.40m shares)
Archon Capital Management LLC Hedge Fund
Percentage owned: 5.04% (1.33m shares)
Cannell Capital, LLC Hedge Fund
Percentage owned: 4.99% (1.31m shares)
Polar Capital Funds Plc - Healthcare Opportunities Fund Mutual Fund
Percentage owned: 4.75% (1.25m shares)
Similar to STIM
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.